Arbutus Biopharma Corp. (ABUS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 17, 2025

$3.20

P/E Ratio

N/A

Market Cap

$606.37M

Jan 29, 2024Mar 1, 2024Apr 5, 2024May 9, 2024Jun 13, 2024Jul 17, 2024Aug 20, 2024Sep 25, 2024Oct 30, 2024Dec 3, 2024Jan 20, 2025$0.00$10.00
  • ONT
Description

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Metrics

Overview

  • HQWarminster, PA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerABUS
  • Price$3.2-0.62%

Trading Information

  • Market cap$606.37M
  • Float77.78%
  • Average Daily Volume (1m)802,366
  • Average Daily Volume (3m)850,804
  • EPS-$0.43

Company

  • Revenue$6.74M
  • Rev growth (1yr)-71.25%
  • Net income-$19.72M
  • Gross margin74.91%
  • EBITDA margin-1,279.69%
  • EBITDA-$17.13M
  • EV$606.61M
  • EV/Revenue89.97
  • P/EN/A
  • P/S89.71
  • P/B5.67
Documents